ATE41739T1 - Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit. - Google Patents

Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit.

Info

Publication number
ATE41739T1
ATE41739T1 AT83109241T AT83109241T ATE41739T1 AT E41739 T1 ATE41739 T1 AT E41739T1 AT 83109241 T AT83109241 T AT 83109241T AT 83109241 T AT83109241 T AT 83109241T AT E41739 T1 ATE41739 T1 AT E41739T1
Authority
AT
Austria
Prior art keywords
oral dosage
release rate
solid oral
weight percent
dosage formulations
Prior art date
Application number
AT83109241T
Other languages
English (en)
Inventor
James Michael Dunn
Original Assignee
Verex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verex Lab filed Critical Verex Lab
Application granted granted Critical
Publication of ATE41739T1 publication Critical patent/ATE41739T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT83109241T 1983-01-03 1983-09-19 Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit. ATE41739T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/455,192 US4461759A (en) 1983-01-03 1983-01-03 Constant release rate solid oral dosage formulations of veropamil
EP83109241A EP0120118B1 (de) 1983-01-03 1983-09-19 Feste orale Dosierungsformulierungen von kardiovaskularen Heilmitteln mit konstanter Freisetzungsgeschwindigkeit

Publications (1)

Publication Number Publication Date
ATE41739T1 true ATE41739T1 (de) 1989-04-15

Family

ID=23807768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83109241T ATE41739T1 (de) 1983-01-03 1983-09-19 Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit.

Country Status (8)

Country Link
US (1) US4461759A (de)
EP (1) EP0120118B1 (de)
JP (1) JPS59128323A (de)
AT (1) ATE41739T1 (de)
AU (1) AU1810783A (de)
CA (1) CA1201064A (de)
DE (1) DE3379496D1 (de)
ZA (1) ZA836582B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US5560909A (en) * 1986-06-03 1996-10-01 Dowelanco Insecticidal compositions and process for preparation thereof
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5093198A (en) * 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
DE4127665A1 (de) * 1991-08-22 1993-02-25 Beiersdorf Ag Galenische matrix
EP0701434B1 (de) * 1993-06-04 2002-08-07 Warner-Lambert Company Zubereitungen enthaltend siliciumdioxid zur verbesserung ihres geschmacks
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
EP1027885B1 (de) * 1999-02-09 2008-07-09 Pfizer Products Inc. Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
DE60000022T2 (de) * 1999-03-05 2002-03-14 Rohm And Haas Co., Philadelphia Verbesserte teilchenförmige Zusammensetzungen
RU2145214C1 (ru) * 1999-07-08 2000-02-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая сердечно-сосудистым действием
BR0016555A (pt) 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
RU2166650C1 (ru) * 2000-03-03 2001-05-10 Смольский Любомир Асафатович Двигатель внутреннего сгорания
CN1390124A (zh) * 2000-09-20 2003-01-08 永光制药有限公司 近视眼的预防、治疗药
EP1404333A1 (de) * 2001-07-06 2004-04-07 Endo Pharmaceuticals Inc. Kontrolliert freisetzende formulierungen von oxymorphon
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
BRPI0419032B8 (pt) * 2004-09-09 2021-05-25 Psicofarma S A De C V composição farmacêutica de liberação prolongada de hidralazina
CN101065139A (zh) * 2004-10-09 2007-10-31 扶瑞药业股份有限公司 眼用药剂递送系统
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742467A (en) * 1953-07-08 1956-04-17 Cassella Farbwerke Mainkur Ag Hypotensive drugs
CH415963A (de) * 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
SE7504049L (sv) * 1975-04-09 1976-10-10 Haessle Ab Colonpreparation
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation

Also Published As

Publication number Publication date
US4461759A (en) 1984-07-24
CA1201064A (en) 1986-02-25
EP0120118A1 (de) 1984-10-03
AU1810783A (en) 1984-09-06
EP0120118B1 (de) 1989-03-29
DE3379496D1 (en) 1989-05-03
JPS59128323A (ja) 1984-07-24
ZA836582B (en) 1984-04-25

Similar Documents

Publication Publication Date Title
ATE41739T1 (de) Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit.
BG50924A3 (bg) Метод за получаване на фармацевтичен състав
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
FR2430410A1 (fr) Phenethanolamines et compositions pharmaceutiques en contenant
SE8700499D0 (sv) Novel pharmacologically active compounds
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
GT198303076A (es) Formulaciones de pastillas de accion prolongada con disolucion paulatina.
FR2510888B1 (fr) Nouvelles compositions a usage pharmaceutique a effet prolonge de liberation d'un ingredient actif
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
EP0038698A3 (en) Pharmaceutical compositions
MA19882A1 (fr) Derives d'acides w-amines, leur preparation et utilisation ainsi que les compositions contenant ces acides.
DE69022314D1 (de) Stabile emulgierte Tretinoin-Cremeformulierungen.
NO891220D0 (no) Middel som inneholder salicylsyre for behandling av lepidose.
YU47973B (sh) S-enantiomerni glutaramidi i postupak za njihovo dobijanje
FR2434804A1 (fr) Derives de la n-phenyl-indoline, leur preparation et leur application comme medicaments
PE56194A1 (es) Composicion analgesica
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
LU81501A1 (fr) Compositions pharmaceutiques comprenant de la trimethoprime,ainsi que des derives d'acides n-ethyl-gamma-pyridone-3-carboxyliques
FR2567756B1 (fr) Nouvelles compositions pharmaceutiques contenant comme ingredient actif l'acetyl-10 triacetoxy-1,8,9 anthracene
JPS53124267A (en) 1-alkoxyacyl-3-(3,5-dihalogenophenyl)hydantoin derivatives, their preparation and bactericides for agricultural and horticultural uses containing the same as active agent
FR2449450A1 (fr) Nouvelles compositions pharmaceutiques utilisables pour le traitement de l'hypertension
IE43848L (en) Pharmaceutical compositions
ES8601692A1 (es) Un procedimiento para la obtencion de preparados del bifonazol con elevada liberacion del producto activo
JPS5246067A (en) Reduction of optically active 5-oxo-2-pyrrolidinacetic acid esters
IT8222908A0 (it) Composizioni utili nella terapia dell'alcoolismo contenenti come principio attivo 3-aroil-butirrolattoni

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee